Our Pipeline
Reimagines Antibody-Drug Conjugates
We’re Focused on Transforming Antibody Therapeutics With Multi-Payload Conjugate™ Technology
CatenaBio is developing Multi-Payload Conjugate (MPC) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody.
CatenaBio is developing Multi-Payload Conjugate (MPC) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody.
Rationale
Single-MOA payload is an enormous limitation of current antibody-drug conjugates (ADCs)
Key Advantage
We can create MPCs unobtainable by existing means
Indication
Solid tumors
Lead Assets
Validated antibody with two mechanistically distinct therapeutic payloads
Undisclosed novel MPC